-
1 Comment
Ningbo Menovo Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 19.9% above its 200 day moving average.
From a valuation standpoint, the stock is 59.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
Ningbo Menovo Pharmaceutical Co., Ltd's total revenue rose by 2.4% to $297M since the same quarter in the previous year.
Its net income has dropped by 19.5% to $34M since the same quarter in the previous year.
Finally, its free cash flow grew by 130.4% to $29M since the same quarter in the previous year.
Based on the above factors, Ningbo Menovo Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002Y25 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 3B |
|---|---|
| Beta | 0.36 |
| PE Ratio | 45.55 |
| Target Price | 21.07 |
| Dividend Yield | None |
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. Ningbo Menovo Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Ningbo, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603538.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
